Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).
about
The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal CancerMaximising the potential of AKT inhibitors as anti-cancer treatmentsEfficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysisTargeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious DiseasesNovel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancerTargeted therapies in gastric cancer and future perspectives.Gastric cancer management: Kinases as a target therapy.Targeting leiomyomas with all-trans-retinoic acid at phosphoinositide 3-kinase pathway suppression: Effective roles of β-catenin and of signaling interactions.AKT in cancer: new molecular insights and advances in drug development.Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.Akt as a target for cancer therapy: more is not always better (lessons from studies in mice).Gastric adenocarcinoma.Targeted therapies for gastric cancer: failures and hopes from clinical trialsAKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.Curcuminoid EF24 enhances the anti-tumour activity of Akt inhibitor MK-2206 through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer.Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism.New therapeutic options opened by the molecular classification of gastric cancer.Emerging Therapies in the Management of Advanced-Stage Gastric CancerNew drug developments in metastatic gastric cancer
P2860
Q26744721-8E35D2EB-523B-4457-8CD4-AE90C8B41837Q28072254-5FA7059A-14BC-4FDD-8216-94F1275FDF3FQ28079362-13DF343C-0E66-42E0-9EFF-AA4E78A7CAAFQ28079596-D5F665A9-AE96-49B8-966D-C575876930EFQ28081001-492D657D-9911-47AC-B2D3-56EF262F1F39Q35072441-3B1EC457-542B-460A-98A5-A2798B17EC7EQ36471685-F0E85767-C285-469D-A711-C21983720BBBQ38749038-14DC38A1-5E11-4B8D-B8FF-1387405A13F8Q38761092-D184B9D9-7915-46CD-93CB-98BEB35019ADQ38846044-BE73D3D5-BA3C-4224-93D0-FDECF30851B2Q38912656-ECD20CA2-4F6D-4BB6-B63D-48AFF3D0A4B4Q39338602-56F6A077-7790-4018-991E-14114B785C3FQ39343374-2638D25C-9190-4A63-99C3-90421563D204Q41340207-8F39E653-B406-4116-93D3-E40009B691AEQ41545361-6861C499-0897-4E92-BBCB-BC2A012651FDQ51736090-DD5283F6-1F2A-44CE-BEFD-54D5B89F7003Q52784526-B4251639-993D-4136-A3AB-F56C9057B050Q55401962-A5B14245-004A-4518-A1B3-0E5833F15523Q55527185-BD538079-A61D-4FD7-80EE-B7816235726EQ57111080-ACCB9135-13BC-4BC0-9935-48D79F24D823Q59136693-5FB25DEE-929D-47FE-A5AB-2A6453219B95
P2860
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase 2 study of MK-2206, an a ...... operative group trial (S1005).
@ast
Phase 2 study of MK-2206, an a ...... operative group trial (S1005).
@en
type
label
Phase 2 study of MK-2206, an a ...... operative group trial (S1005).
@ast
Phase 2 study of MK-2206, an a ...... operative group trial (S1005).
@en
prefLabel
Phase 2 study of MK-2206, an a ...... operative group trial (S1005).
@ast
Phase 2 study of MK-2206, an a ...... operative group trial (S1005).
@en
P2093
P2860
P356
P1433
P1476
Phase 2 study of MK-2206, an a ...... operative group trial (S1005).
@en
P2093
Aram F Hezel
Charles D Blanke
Gina M Vaccaro
Hagen F Kennecke
Howard J Lim
Joaquina C Baranda
Ramesh K Ramanathan
Shannon L McDonough
Syma Iqbal
Tara E Seery
P2860
P304
P356
10.1002/CNCR.29363
P407
P577
2015-03-30T00:00:00Z